Fundraising FoxAmaryllis Therapeutics, Inc.
Cambridge, US · Founded 2024 · 2 known investors
Find your way into Amaryllis Therapeutics, Inc.
Sign up to see every warm intro you have to Amaryllis Therapeutics, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Amaryllis Therapeutics, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Amaryllis Tx develops tissue-targeted drug delivery by mapping tissue-specific glycan signatures and designing peptides that recognize them, using in silico and in vivo screening. Its lead peptide enables subcutaneously injected payloads such as antibodies, mRNA, ASO, and siRNA to cross the blood-brain barrier, initially targeting the brain.
Founders & leadership
JK
Jeongseuk KangExecutive
Board
EK
Emmanouil KaragiannisBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$1.5M disclosed across 1 round · 2024
▶$1.5MraisedSep 2024 · 1 investors · OtherRule 506(b)
▶$1.5MraisedSep 2024 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Jeongseuk KangExecutive Officer, Director
- Emmanouil KaragiannisDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Amaryllis Therapeutics, Inc. do?
- Amaryllis Tx develops tissue-targeted drug delivery by mapping tissue-specific glycan signatures and designing peptides that recognize them, using in silico and in vivo screening. Its lead peptide enables subcutaneously injected payloads such as antibodies, mRNA, ASO, and siRNA to cross the blood-brain barrier, initially targeting the brain.
- Who are Amaryllis Therapeutics, Inc.'s investors?
- Amaryllis Therapeutics, Inc.'s investors include ACVC Partners, The Ventures Co.
- How much funding has Amaryllis Therapeutics, Inc. raised?
- Amaryllis Therapeutics, Inc. has disclosed $1.5M raised across 1 round.
- Where is Amaryllis Therapeutics, Inc. headquartered?
- Amaryllis Therapeutics, Inc. is headquartered in Cambridge, US.